VLP is a biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment.
VLP's vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) Technology.
VLPT was co-founded in 2013 by Wataru Akahata, Ryuji Ueno, and Sachiko Kuno. The company is headquartered in Gaithersburg, Maryland.
VLPT is currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, and novel coronavirus disease (COVID-19) using VLPT's proprietary platform technologies.
VLP's malaria vaccine candidate VLPM01 clinical trial designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers.
VLPT is backed by MIYAKO Capital C, Nobelpharma Co., MUFG Bank, Sojitz Corporation, SK Impact Fund, RJ Fund, Konishiyasu Co., and others. The company raised $21M in Series A-1 round on Dec 27, 2021. This brings VLPT's total funding to $40.9M to date.